搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
pharmaphorum
1 小时
PBM reform dropped in Congress' funding package
The stripping of the legislation from the short-term funding package was described as a "missed opportunity" by the National ...
pharmaphorum
2 小时
FDA clears Ionis drug as first therapy for rare disease FCS
Ionis Pharma's olezarsen has become the first FDA-approved drug therapy for adults with familial chylomicronaemia syndrome ...
pharmaphorum
4 小时
Lilly grabs first-ever FDA nod for a sleep apnoea drug
Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...
pharmaphorum
5 小时
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
pharmaphorum
2 天
World Without Disease initiative: 2024 update
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and ...
pharmaphorum
2 天
Biogen claims first with FDA nod for biosimilar Actemra
Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...
pharmaphorum
3 天
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after ...
pharmaphorum
3 天
Vertex weakens after neuropathic pain trial reads out
Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...
pharmaphorum
3 天
Novo completes $16.5bn takeover of Catalent
Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...
pharmaphorum
3 天
Neuralink rival Precision raises $102m, and other financings
While Neuralink has been grabbing headlines due to its association with controversial billionaire Musk, other companies - ...
pharmaphorum
3 天
Roche's Parkinson's hope fails second clinical trial
An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...
pharmaphorum
3 天
Ottimo raises $140m for its PD-1/VEGF cancer drug
Anglo-US biotech Ottimo Pharma has completed a big early-stage biotech financing, raising $140 million for its PD-1 and VEGF ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈